Endologix Reports Positive 1-Year Results from the Ovation LUCY Study

Endologix (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, announced 1-year results from the LUCY (Evaluation of FemaLes who are Underrepresented Candidates for Abdominal Aortic AneurYsm Repair) registry as reported on Saturday, June 23rd at the 2018 Society for Vascular Surgery Annual Meeting.

As quoted in the press release:

The LUCY study is a prospective, consecutively enrolling, non-randomized, multi-center, post-market registry evaluating the Ovation System for the endovascular treatment of abdominal aortic aneurysms (AAA) in women.³ The study enrolled a total of 225 patients, including 76 females in the treatment group and 149 males in the control group, at 39 sites in the U.S. The primary endpoint of the study was the 30-day Major Adverse Event (“MAE”) rate and secondary endpoints including serious and non-serious adverse events through one year.

The 1-year LUCY data showed that, despite having more complex anatomy at the time of the index procedure than men, women had similar outcomes to men following treatment with the ultra-low profile (14F) Ovation device:

• Freedom from AAA-related morality: 100% in women vs 98.6% in men
• Freedom from reintervention for Type 1a endoleak: 98.6% in women vs 97.9% in men
• Freedom from rupture: 100% in both women and men
• Freedom from conversion: 100% in both women and men
• Freedom from all device-related reintervention: 97.2% in both women and men

Click here to read the full press release.